These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31746305)

  • 1. Coumarin-Fatty Acid Conjugates as Potential ERα/AKT-1 Antagonists for ER Positive Breast Cancer.
    Selvaraj J; John JBA; Joghee NM; Antony J; Wadhwani A; Natarajan J
    Anticancer Agents Med Chem; 2020; 20(4):437-449. PubMed ID: 31746305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants.
    Kurtanović N; Tomašević N; Matić S; Mitrović MM; Kostić DA; Sabatino M; Antonini L; Ragno R; Mladenović M
    Eur J Med Chem; 2022 Jan; 227():113869. PubMed ID: 34710747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells.
    Hua KT; Way TD; Lin JK
    Mol Carcinog; 2006 Aug; 45(8):551-60. PubMed ID: 16637063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
    Nehybova T; Smarda J; Daniel L; Brezovsky J; Benes P
    J Steroid Biochem Mol Biol; 2015 Aug; 152():76-83. PubMed ID: 25934092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formononetin promotes proliferation that involves a feedback loop of microRNA-375 and estrogen receptor alpha in estrogen receptor-positive cells.
    Chen J; Zhang X; Wang Y; Ye Y; Huang Z
    Mol Carcinog; 2016 Mar; 55(3):312-9. PubMed ID: 25663261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a multi-target compound for estrogen receptor-positive (ER
    Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
    Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
    J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway.
    Sui JQ; Xie KP; Zou W; Xie MJ
    Asian Pac J Cancer Prev; 2014; 15(15):6247-51. PubMed ID: 25124606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-3 poly-unsaturated fatty acids shift estrogen signaling to inhibit human breast cancer cell growth.
    Cao W; Ma Z; Rasenick MM; Yeh S; Yu J
    PLoS One; 2012; 7(12):e52838. PubMed ID: 23285198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells.
    Li HJ; Wang LY; Qu HN; Yu LH; Burnstock G; Ni X; Xu M; Ma B
    Mol Cell Endocrinol; 2011 May; 338(1-2):28-37. PubMed ID: 21356271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling.
    Pham TH; Page YL; Percevault F; Ferrière F; Flouriot G; Pakdel F
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ERα.
    Vethakanraj HS; Sesurajan BP; Padmanaban VP; Jayaprakasam M; Murali S; Sekar AK
    Anticancer Drugs; 2018 Jan; 29(1):50-60. PubMed ID: 29023248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.